Solve Therapeutics
Last verified 2026-06-17. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $321.0Mattributed |
|---|---|
| Latest round | series-d+, $120.0M, 2025-11-01attributed |
| Founded | unknown |
| Headquarters | San Diego, United States |
| Industry | bio |
| Stage | series-b+ |
| Website | solvetx.com |
Solve Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates for solid tumors. It serves patients with cancers driven by selectively expressed tumor antigens, with leads SLV-154 and SLV-324 in Phase 1 trials. Its CloakLink hydrophilic linker improves ADC stability and widens the therapeutic window.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-11-01 | series-d+ | $120.0M | undisclosed |
Detected tech stack
nginx
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $120.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $321.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | solvetx.com, read 2026-06-17 |
| Description | self-reported | solvetx.com, read 2026-06-17 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.